North America Biopharmaceutical Contract Manufacturing Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Biologics and Biosimilar), Source (Microbial and Mammalian), Application (Commercial and Clinical), and Therapeutic Area (Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and Others)
The North America Biopharmaceutical Contract Manufacturing Market is poised for significant growth, with projections indicating it will reach approximately US$ 41,018.6 million by 2031, up from US$ 16,488.3 million in 2024. This growth trajectory reflects a robust compound annual growth rate (CAGR) of 14.0% from 2025 to 2031.
Executive Summary
The biopharmaceutical contract manufacturing sector in North America is expanding rapidly, driven by a combination of a strong pharmaceutical industry, cutting-edge technology, and stringent regulations that promote high quality and innovation. The United States is at the forefront of this market, supported by a vast pharmaceutical base, substantial investments in research and development, and a strong presence of leading contract development and manufacturing organizations (CDMOs). These CDMOs provide a wide array of services that facilitate faster drug development and commercialization.
Canada is also emerging as a key player in this market, particularly in specialized areas such as biologics, vaccines, and sterile manufacturing. The increasing trend of outsourcing among pharmaceutical and biotechnology companies is a significant factor in this growth, as it allows firms to reduce costs, enhance operational flexibility, and expedite the market introduction of new products. Coupled with ongoing technological advancements and strategic partnerships, these elements reinforce North America's position as a global leader in biopharmaceutical contract manufacturing.
Market Segmentation Analysis
The North America Biopharmaceutical Contract Manufacturing Market can be segmented based on various criteria:
Biologics are increasingly recognized as the cornerstone of modern medicine, particularly for treating complex and chronic diseases such as cancer, autoimmune disorders, and genetic conditions. Key biologics include monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins. According to the National Cancer Institute, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were reported in 2022, highlighting the growing demand for biologics. This demand is driving pharmaceutical manufacturers to collaborate with contract manufacturing organizations (CMOs) that specialize in biologics production.
The manufacturing of biologics is inherently complex, requiring specialized equipment, expertise, and facilities. The lengthy production timelines and high costs associated with establishing in-house manufacturing capabilities make outsourcing an attractive option for many companies. CMOs provide the necessary infrastructure and expertise to scale production efficiently, enabling drug developers to meet market demands without incurring significant capital expenditures. Notable manufacturers like Roche and Bristol-Myers Squibb have successfully developed monoclonal antibody-based biologics, such as Herceptin and Opdivo, in collaboration with CMOs, revolutionizing cancer treatment and significantly increasing the demand for contract manufacturing services.
Country Insights
The North America Biopharmaceutical Contract Manufacturing Market is primarily segmented by country into the United States, Canada, and Mexico, with the United States holding the largest market share in 2024. The US market benefits from the presence of leading contract research organizations and manufacturers, supported by a well-established healthcare industry that fosters a conducive environment for outsourcing research and development (R&D) and clinical trial services.
Contract research organizations play a vital role in the biotechnology, pharmaceutical, and medical device sectors by offering outsourced research services that expedite the often lengthy and complex drug development process. The landscape for these organizations in the US is evolving rapidly due to the increasing demand for faster drug and technology development. The regulatory environment, particularly initiatives like real-time assessment by the US FDA, significantly influences the operations of contract research organizations, allowing for simultaneous data evaluation during clinical trials.
Key Players
Prominent companies in the North America Biopharmaceutical Contract Manufacturing Market include Boehringer Ingelheim International GmbH, Lonza Group AG, AbbVie Inc, Samsung Biologics Co., Ltd., WuXi Biologics Inc, Merck KGaA, Ajinomoto Co., Inc., Cytiva, and AGC Biologics AS. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and deliver innovative solutions to their clients.
Executive Summary
The biopharmaceutical contract manufacturing sector in North America is expanding rapidly, driven by a combination of a strong pharmaceutical industry, cutting-edge technology, and stringent regulations that promote high quality and innovation. The United States is at the forefront of this market, supported by a vast pharmaceutical base, substantial investments in research and development, and a strong presence of leading contract development and manufacturing organizations (CDMOs). These CDMOs provide a wide array of services that facilitate faster drug development and commercialization.
Canada is also emerging as a key player in this market, particularly in specialized areas such as biologics, vaccines, and sterile manufacturing. The increasing trend of outsourcing among pharmaceutical and biotechnology companies is a significant factor in this growth, as it allows firms to reduce costs, enhance operational flexibility, and expedite the market introduction of new products. Coupled with ongoing technological advancements and strategic partnerships, these elements reinforce North America's position as a global leader in biopharmaceutical contract manufacturing.
Market Segmentation Analysis
The North America Biopharmaceutical Contract Manufacturing Market can be segmented based on various criteria:
- By Product Type: The market is divided into Biologics and Biosimilars, with Biologics holding the largest market share in 2024.
- By Source: The segmentation includes Microbial and Mammalian sources, where Microbial is the leading segment in 2024.
- By Application: The market is categorized into Commercial and Clinical applications, with Commercial applications dominating in 2024.
- By Therapeutic Area: This includes Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and others, with Oncology being the largest segment in 2024.
Biologics are increasingly recognized as the cornerstone of modern medicine, particularly for treating complex and chronic diseases such as cancer, autoimmune disorders, and genetic conditions. Key biologics include monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins. According to the National Cancer Institute, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were reported in 2022, highlighting the growing demand for biologics. This demand is driving pharmaceutical manufacturers to collaborate with contract manufacturing organizations (CMOs) that specialize in biologics production.
The manufacturing of biologics is inherently complex, requiring specialized equipment, expertise, and facilities. The lengthy production timelines and high costs associated with establishing in-house manufacturing capabilities make outsourcing an attractive option for many companies. CMOs provide the necessary infrastructure and expertise to scale production efficiently, enabling drug developers to meet market demands without incurring significant capital expenditures. Notable manufacturers like Roche and Bristol-Myers Squibb have successfully developed monoclonal antibody-based biologics, such as Herceptin and Opdivo, in collaboration with CMOs, revolutionizing cancer treatment and significantly increasing the demand for contract manufacturing services.
Country Insights
The North America Biopharmaceutical Contract Manufacturing Market is primarily segmented by country into the United States, Canada, and Mexico, with the United States holding the largest market share in 2024. The US market benefits from the presence of leading contract research organizations and manufacturers, supported by a well-established healthcare industry that fosters a conducive environment for outsourcing research and development (R&D) and clinical trial services.
Contract research organizations play a vital role in the biotechnology, pharmaceutical, and medical device sectors by offering outsourced research services that expedite the often lengthy and complex drug development process. The landscape for these organizations in the US is evolving rapidly due to the increasing demand for faster drug and technology development. The regulatory environment, particularly initiatives like real-time assessment by the US FDA, significantly influences the operations of contract research organizations, allowing for simultaneous data evaluation during clinical trials.
Key Players
Prominent companies in the North America Biopharmaceutical Contract Manufacturing Market include Boehringer Ingelheim International GmbH, Lonza Group AG, AbbVie Inc, Samsung Biologics Co., Ltd., WuXi Biologics Inc, Merck KGaA, Ajinomoto Co., Inc., Cytiva, and AGC Biologics AS. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and deliver innovative solutions to their clients.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET LANDSCAPE
4.1 PEST Analysis
5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
6.2 North America Biopharmaceutical Contract Manufacturing Market Forecast and Analysis
7. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Biosimilar
7.2.1 Overview
7.2.2 Biosimilar: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY SOURCE
8.1 Microbial
8.1.1 Overview
8.1.2 Microbial: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Mammalian
8.2.1 Overview
8.2.2 Mammalian: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Commercial
9.1.1 Overview
9.1.2 Commercial: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Clinical
9.2.1 Overview
9.2.2 Clinical: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
10.1 Oncology
10.1.1 Overview
10.1.2 Oncology: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Autoimmune Disorders
10.2.1 Overview
10.2.2 Autoimmune Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Respiratory Disorders
10.3.1 Overview
10.3.2 Respiratory Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4 Metabolic Disorders
10.4.1 Overview
10.4.2 Metabolic Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5 Neurology
10.5.1 Overview
10.5.2 Neurology: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6 Infectious Diseases
10.6.1 Overview
10.6.2 Infectious Diseases: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - COUNTRY ANALYSIS
11.1 North America
11.1.1 North America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.1.1 North America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.2.2 United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 United States: North America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.1.2.2.2 United States: North America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.1.2.2.3 United States: North America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.1.2.2.4 United States: North America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.2.3.3 Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Canada: North America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.2.3.3.2 Canada: North America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.2.3.3.3 Canada: North America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.2.3.3.4 Canada: North America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.3.4.4 Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 Mexico: North America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.3.4.4.2 Mexico: North America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.3.4.4.3 Mexico: North America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.3.4.4.4 Mexico: North America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Boehringer Ingelheim International GmbH
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Lonza Group AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 AbbVie Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Samsung Biologics Co Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 WuXi Biologics Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Ajinomoto Co Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Cytiva
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AGC Biologics AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET LANDSCAPE
4.1 PEST Analysis
5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
6.2 North America Biopharmaceutical Contract Manufacturing Market Forecast and Analysis
7. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Biosimilar
7.2.1 Overview
7.2.2 Biosimilar: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY SOURCE
8.1 Microbial
8.1.1 Overview
8.1.2 Microbial: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Mammalian
8.2.1 Overview
8.2.2 Mammalian: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Commercial
9.1.1 Overview
9.1.2 Commercial: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Clinical
9.2.1 Overview
9.2.2 Clinical: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
10.1 Oncology
10.1.1 Overview
10.1.2 Oncology: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Autoimmune Disorders
10.2.1 Overview
10.2.2 Autoimmune Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Respiratory Disorders
10.3.1 Overview
10.3.2 Respiratory Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4 Metabolic Disorders
10.4.1 Overview
10.4.2 Metabolic Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5 Neurology
10.5.1 Overview
10.5.2 Neurology: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6 Infectious Diseases
10.6.1 Overview
10.6.2 Infectious Diseases: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. NORTH AMERICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - COUNTRY ANALYSIS
11.1 North America
11.1.1 North America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.1.1 North America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.2.2 United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 United States: North America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.1.2.2.2 United States: North America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.1.2.2.3 United States: North America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.1.2.2.4 United States: North America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.2.3.3 Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Canada: North America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.2.3.3.2 Canada: North America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.2.3.3.3 Canada: North America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.2.3.3.4 Canada: North America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.3.4.4 Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 Mexico: North America Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.3.4.4.2 Mexico: North America Biopharmaceutical Contract Manufacturing Market Share - by Source
11.3.4.4.3 Mexico: North America Biopharmaceutical Contract Manufacturing Market Share - by Application
11.3.4.4.4 Mexico: North America Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Boehringer Ingelheim International GmbH
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Lonza Group AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 AbbVie Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Samsung Biologics Co Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 WuXi Biologics Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Ajinomoto Co Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Cytiva
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AGC Biologics AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
LIST OF TABLES
Table 1. North America Biopharmaceutical Contract Manufacturing Market Segmentation
Table 3. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 6. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 8. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 11. United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 12. United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 13. Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 14. Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 15. Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 17. Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 19. Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 21. Heat Map Analysis by Key Players
Table 1. North America Biopharmaceutical Contract Manufacturing Market Segmentation
Table 3. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 6. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 8. North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 11. United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 12. United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 13. Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 14. Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 15. Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 17. Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 19. Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 21. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. North America Biopharmaceutical Contract Manufacturing Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. North America Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. North America Biopharmaceutical Contract Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Biologics: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Biosimilar: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. North America Biopharmaceutical Contract Manufacturing Market Share (%) - by Source, 2024 and 2031
Figure 11. Microbial: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Mammalian: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. North America Biopharmaceutical Contract Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 14. Commercial: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Clinical: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. North America Biopharmaceutical Contract Manufacturing Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 17. Oncology: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Autoimmune Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Respiratory Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Metabolic Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Neurology: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Infectious Diseases: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Others: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. North America Biopharmaceutical Contract Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Company Positioning & Concentration
Figure 1. North America Biopharmaceutical Contract Manufacturing Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. North America Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. North America Biopharmaceutical Contract Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Biologics: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Biosimilar: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. North America Biopharmaceutical Contract Manufacturing Market Share (%) - by Source, 2024 and 2031
Figure 11. Microbial: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Mammalian: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. North America Biopharmaceutical Contract Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 14. Commercial: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Clinical: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. North America Biopharmaceutical Contract Manufacturing Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 17. Oncology: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Autoimmune Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Respiratory Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Metabolic Disorders: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Neurology: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Infectious Diseases: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Others: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. North America Biopharmaceutical Contract Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. United States: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Canada: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Mexico: North America Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Company Positioning & Concentration
